STOCKS TELEGRAPH

Author: ST Staff

Intrusion Inc. (INTZ) stock had plunged in the premarket trading session; here’s why

Interruption Inc. (INTZ stock) shares were plunging at last check – 40.24% to exchange at $5.08 in pre-market. INTZ’ stock had previously closed the session at a loss of – 15.00% at $8.50. The INTZ stock volume traded 0.66 million offers, which was higher than the normal everyday volume of 0.32 million offers inside the previous 50 days. INTZ shares have ascended by 40.03% in the course of the most recent year, and they have dropped somewhere around – 15.17% in the previous week. In the course of recent months, the stock has lost – 45.93%, while in the course of recent months, it has shed – 63.11%. Further, the organization has a current market of $139.15 million and its exceptional offers remained at 17.54 million.

All there is to know about Intrusion as a SaaS company

Intrusion is considered to be a Software-Application company that specifically works on a Software as a Service (SaaS) business model. The services of this company are expanded along with the operations all across the United States. Its operations include developing, marketing, and supporting its products. The types of SaaS service they provide include advanced persistent threat detection, cybercrime, products entity identification, and data mining. It offers INTRUSION Shield, an detection and reaction security-as-a-service solution for distinguish and stop Zero-Day assaults and ransomware. The organization additionally gives INTRUSION TraceCop, a major information instrument that contains a stock of network selectors and improvements to help criminological examinations; and INTRUSION Savant, an organization observing arrangement that utilizes the information accessible in TraceCop to distinguish dubious traffic progressively.

Furthermore, the company also has its business diversified by engaging in the reselling of computers, servers that come from various vendors. It provides pre and post-sales services and technical support. These support include network security plan, framework establishment, and specialized counseling administrations. The organization serves US national government elements, state and nearby government substances, and organizations going from mid-market to enormous undertakings through an immediate deals power and worth added affiliates. The organization was once in the past known as Intrusion.com, Inc. also, changed its name to Intrusion Inc. in November 2001. Interruption Inc. was established in 1983 and is settled in Plano, Texas.

INTZ stock announced preliminary revenue for the Q2 2021

The company has announced its preliminary revenue as part of the financial result for the performance of the second quarter of the year 2021. The expected revenue is going to be around the range of $1.9 million and $2.0 million. The company is also looking for various funding sources since INTRUSION accepts that extra capital might be needed to accomplish benefit, it has drawn in a speculation banking firm to assess sources, and furthermore possibly productive longer-term key alternatives that may help INTRUSION develop, accomplish its working destinations and augment investor esteem.

Shield’s reputation is starting to exceed its name as global interest for its solutions increases. However, INTZ stock has encountered a more slow than expected sales growth because the client assessment cycles are taking longer here at the company than normally seen in most undertaking security deals associations. In light of client criticism, the Company stays positive about Shield’s adequacy and the important insurance it offers to clients in assisting them with battling the developing conflict on cybercrime. The teams at INTZ stock keeps on working extensively with accomplices and the business channel to additional slope testing with expected clients and convert a developing pipeline of client commitment into repeating memberships.

July 20, 2021
Why Has The MediWound (MDWD) Stock Price Rocketed 16% Premarket?
In premarket trading on Tuesday, MediWound Ltd. (MDWD) shares gained 16.04% to $5.21. MediWound stock decreased -3.02% to close at $4.49 last trading session. MDWD stock traded 0.14 million shares, which is less than the average daily volume of 0.4 million shares for the last 50 days. Following news of positive overall results from a phase 3 pediatric study, MDWD stock is surging in pre-hour trades.

What was the purpose of that MDWD study?

In addition to developing, manufacturing, and distributing biopharmaceutical products for tissue repair and regeneration, MediWound manufactures novel, cost-effective, biotechnological products. MDWD develops bioactive therapies focused on next-generation wound care, burn treatment, and tissue repair using its enzymatic technology platform.

Medical Devices and Diagnostics Division of MDWD has developed NexoBrid, a commercial orphan biological product designed to treat thermal burns without the need for surgery or anesthesia. NexoBrid by MDWD is a bromelain-based biological product that is sterile, nontoxic, and induces the removal of burn eschar in four hours without affecting surrounding healthy tissue.

Positive topline results were announced today by MediWound for its pivotal phase 3 pediatric clinical studies (CIDS – Children Innovation Debridement Study).
- Compared with a standard of care (SOC), MDWD evaluated the effectiveness and safety of NexoBrid in treating children suffering severe thermal burns.
- In the MDWD study, the three primary endpoints were statistically significant.
- With NexoBrid, the time required for the complete removal of eschar as well as the required amount of surgical excision (surgical need) was significantly shortened, while the scar quality was comparable to SOC.
- A secondary endpoint of the MDWD study showed a reduction in surgical excision and reduction in the need for autograft in deep partial burns alongside the primary endpoint.
- In the MDWD study, a favorable trend in eschar removal process blood loss was seen.
- NexoBrid was also found to be safe and well-tolerated in the MDWD study.
- In MDWD, mo detriment to wound healing has been observed.
- The time it took for patients treated with NexoBrid to complete wound closure was comparable to that of patients treated with SOC.
- With NexoBrid, the estimated median time for wound closure was 32 days, while with SOC, it was 34 days.
- NexoBrid was found in all subjects to be safe and well tolerated by the study DSMB (Data Safety Monitoring Board).
- There were no safety concerns identified in the study population.
A brief analysis of the MDWD study:

The results of the study, that were robust across all primary endpoints, corroborated MDWD’s pivotal phase 3 clinical studies in adult patients, and strongly demonstrated NexoBrid’s positive effects on pediatric burn patients. It is encouraging for MediWound (MDWD) to see that its NexoBrid could be a treatment option for pediatric burn patients with high-level results.
July 20, 2021
SolarWinds Corp. (SWI) Stock Plummets Following Announcement of Completion of Spin-Off Business

SolarWinds Corp. (SWI) stock prices were down by a massive 47.37% as of the market closing on July 19^th, 2021, bringing the price per share down to USD$8.92 at the end of the trading day. Subsequent premarket fluctuations have seen the stock fall by another 37.00%, bringing it down to USD$10.66.

Spin-Off Business

July 20^th, 2021 saw the company announce the completion of its previously announced spin-off of the SWI managed service provider (MSP) business into N-able, Inc., a standalone public company that is traded separately. With the completion of the transaction having taken place on July 19^th, 2021, the newly listed spin-off company will facilitate the provision of cloud-based software solutions for managed service providers.

Birth of N-able

This, in turn, will allow the MSPs to support digital transformation and growth within small and medium-sized enterprises. While N-able will be listed on the New York Stock Exchange under the NABL ticker, SWI will retain control of its Core IT Management business, which will primarily focus on Providing IT infrastructure management software to corporate IT organizations.

Financial Forecasts

Following the company’s initial review of its financial performance for the second quarter of 2021, SWI anticipates reporting total revenue ranging from USD$260.8 million to USD$262 million. This forecast accounts of roughly 6% year-over-year growth, including the company’s Core IT Management revenue-generating USD$176 million to USD$177 million, representing a 2% year-over-year increase. GAAP net loss for the second quarter of 2021 is expected to be in the range of USD$10.4 million and USD$11.3 million.

Private Placement Offering

July 12^th, 2021 saw the company announce having entered into a definitive agreement with various institutional accredited investors in regard to a private placement financing transaction. The transaction is expected to generate roughly USD$225 million before the deduction of expenses related to the offering. As per the agreement, the company will issue a total of 20,623,282 shares of its common stock, with each share being priced at USD$10.91. Having culminated on July 19^th, 2021, N-able will diver the net proceeds generated from the offering to SolarWinds before the closing of the distribution. The capital generated is expected to be used in distribution to its stockholders, as well as to pay down existing third-party indebtedness.

Future Outlook for SWI

Armed with the influx of capital from the offering having resulted in a healthier balance sheet, SWI is poised to capitalize on the opportunities presented to it and its spin-off business. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate a continued trajectory of success for the company.

July 20, 2021
Moderna Inc. (MRNA) stock surged in the premarket trading session; here’s why

We can see that Moderna Inc. (MRNA stock) shares had surged in pre-market by 1.4% to $317.99 at last check. In the previous session, MRNA’s stock gained 9.48% to close at $313.59. The MRNA stock volume traded 35.53 million shares, which was greater than 9.31 million shares of the average daily volume within the past 50 days. In the past year, up-to-date MRNA stock has surged by 230.62%. Further, MRNA stock is currently valued in the market at $114.15 billion and has 400.00 million outstanding shares.

All there is to know about Moderna Inc.

Moderna Inc. is a biotech company that has become specifically famous for creating corona-virus vaccines that are based on messenger RNA. The company along with vaccines also creates therapeutics that are for the treatment of infectious and rare diseases, cardiovascular diseases, immune-oncology, and autoimmune diseases. The company has a total of 24 developmental programs along with in which it has 13 programs in clinical trials, as of March 2021. The developmental programs come in six modalities which comprise of vaccines; cancer and prophylactic, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, intratumoral immune-oncology, and systemic intracellular therapeutics. Being a massive leader in the biotech industry, it has key partnerships with AstraZeneca PLC, Merck and Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill and Melinda Gates Foundation. Moderna, Inc. likewise has coordinated efforts with Lonza Ltd. for the production of COVID-19 immunization; and Catalent Inc., LaboratoriosFarmaceuticosRovi, S.A., Recipharm, and Lonza Group for fill-complete the process of assembling of its COVID-19 antibody up-and-comer, just as Aldevron, LLC for supporting COVID-19 immunization and extra projects in organization’s clinical improvement pipeline. The organization was earlier known as Moderna Therapeutics, Inc. furthermore, changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was established in 2010 and is settled in Cambridge, Massachusetts.

An additional order of 50 million doses ordered from Moderna by Japan’s Health, Labor, and Welfare Ministry.

The countries are on a race to secure as many supplies of vaccines from private manufacturers as possible. Every country is stocking up on at least the same number of vaccines as its population if not twice of that or more. Japan has announced that it has ordered 50 million additional doses of Moderna vaccine for Covid-19 along with its new variant booster vaccine candidate. This new variant booster candidate is still in trials and awaiting authorization from the FDA. The vaccine will begin delivering in 2022, which is expected due to the large demand for vaccines by countries that have filled up the orders for vaccine till the end of 2021 already for international manufacturers like Moderna. This new stockpile arrangement is exclusive of the earlier deal for 50 million dosages in 2021 bringing about a sum of 100 million doses for Japan. Moderna is answerable for the assembling and supply of Moderna’s antibody up-and-comer, and Takeda, with the help of the MHLW and Moderna, is liable for all import, neighborhood administrative, improvement, and conveyance exercises in Japan for these extra 50 million portions starting in 2022.

This request was explicitly declared today by the Ministry of Health, Labor and Welfare of Japan (MHLW) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) who have consented to buy and appropriate these extra immunization dosages.

July 20, 2021
Why Did GTYH Stock Go Higher In Pre-hours Trading?
On Tuesday morning, GTY Technology Holdings Inc. (GTYH) was up 4.82% at $7.17 during the pre-market hours. During the last trading session, GTYH stock lost -4.47% to close at $6.84. Price range for GTYH shares was $6.68 – $7.15.

There were 64795 shares traded on GTYH stock, which was below its daily average of 0.21 million shares over the past 100 days. In the last five days, GTYH stock has fallen -3.25%, while in the last month, it has lost -3.93%. As a result of an improved public sector platform announced by its subsidiary, GTYH stock price is climbing.

Which GTYH subsidiary made that move?

Leading companies in the public sector have joined forces with GTY Technology to redefine stakeholder engagement and resource management. GTYH offers six business units that cover functions in procurement, payments, grant management, budgeting, and permitting for state and local governments, educational institutions, and healthcare organizations. GTYH suites include Bonfire, CityBase, eCivis, OpenCounter, Questica and Sherpa.

Budget 2021.2, the newest version of the company’s flagship application, Questica Budget, has been released by GTY Technology-subsidiary Questica Inc.
- Questica is a subsidiary of GTYH, which specializes in public sector cloud solutions.
- With the introduction of Questica Budget 2021.2, the process of public-sector budgeting was made simpler and more collaborative.
- Customers and a team of user research participants, including cities and counties, healthcare companies, education institutions, courts, utility companies, and public school boards, provided valuable input to GTYH subsidiary.
- Adding new features to the successful Questica Budget 2020.2, this upgraded version now includes a task interface and a calendar integrated with the budget.
- Using the platform, authorized users can directly tag teammates, engage with any budget element on the platform, and ensure that only authorized staff members can see sensitive data.
- Additionally, “social budgeting” features will be introduced to the platform.
- The new in-product features provided by GTYH’s subsidiary are based on Microsoft Azure Cloud technology, enabling the public sector to be more strategic, efficient, and transparent.
- With an innovative data grid, intuitive interface, and advanced analytics, Questica Budget 2021.2 allows clients to find insights, reduce data reconciliation, and make informed decisions.
- Thus, governments and organizations in the public sector will be able to spend fewer resources on manual operations and administrative overhead and more time on planning for the future and analyzing past performance.
GTYH’s perspective on the improved platform:

An 18-month effort has been put into building and refining Questica Budget by GTYH subsidiary’s team based on feedback received from the public sector. The Questica Budget is the budgeting solution created especially for the public sector, and GTY Technology (GTYH) sees that it is utilized by governments, non-profits, high schools, colleges, and universities across North America.
July 20, 2021
Atossa Therapeutics, Inc. (ATOS) stock is declining in Pre-Market today: Why is it so?

Shares of the Atossa Therapeutics, Inc. (ATOS) stock were declining in the pre-market trading session today on July 20, 2021, after dropping as much as 13.33% at the previous closing. The ATOS stock price saw a drop of 0.51% to reach $3.88 a share and the trading volume was 24,759,902 as of this writing. Let’s understand why ATOS stock is bearish today.

What’s Happening?

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery and development of medicines for oncology and infectious diseases. There seems to be no news related to Atossa Therapeutics in today’s date to justify the bearish sentiment. No press release or announcement has been made to support the declining per share price of the ATOS stock. For now,it is better to look at some recent events of ATOS stock.

Atossa fight against Covid-19:

Though many western countries have made significant progress in vaccinating their population, still Covid-19 is the major health concern due to its evolving variants that are more deadly. Atossa is developing AT-H201 in order to treat patients suffering from moderate covid-19. Attosa is now planning to treat a group of 60 mixed patients that are either recovered or moderately ill hospitalized covid-19 patients in a phase ½a placebo-controlled study by utilizing the combination of blood thinner Heparin and the anti-inflammatory N-acetylcysteine, with AT-H201.

The Analyst Opinion:

Maxim analyst Jason McCarthy considered the combination of N-acetylcysteine and Heparin as “intriguing”. McCarthy thinks that the AT-H201 is the only reason that makes ATOS stock more attractive as far as investment in stocks is concerned. He rated the ATOS stock “buy” and set a $7 target price. The ATOS stock is weighed by only two analysts, and both rated the stock “ buy”.

Performance in June:

ATOS stock had made significant progress in June 2021 as it became part of Russell 2000 and Russell 3000 indexes. Moreover, the Swedish Medical Product Agency (MPA) approved the commencement of Endoxifen’s second phase clinical trial study. Endoxifen is used to treat the mammographic breast density (MBD) that is affecting 10 million women in the U.S alone.

Wrap Up:

The ATOS stock is declining in the stock market without any obvious reason. Such rises and falls don’t affect the long-term investors who mainly focus on stock’s overall growth and developments.

July 20, 2021
What Led The TTOO Stock To Increase In Premarket Session?
The share price of T2 Biosystems Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens, was up 3.88% in pre-market trading at $1.07. Last session, TTOO closed at $1.03, losing -0.96% or $0.01. The price of each TTOO share fluctuated from $1.00 to $1.04 during the past session. A total of 3.2 million shares of TTOO stock were traded on the day, less than the company’s average daily volume of 4.66 million over the previous 50 days and a fraction of share volume of 8.17 million for the year to date.

TTOO’s stock has suffered a decline of 39.59% in the past 12 months, and it has fallen -4.63% in the last week. TTOO stock has declined by -43.09% over the last six months, and by -12.71% over the last three months. Since the start of this year, the stock has lost -16.94%. Following granting of the inducement award, TTOO stock is rising.

Who is TTOO granting the award to?

Using T2 Biosystems’ products, clinicians are able to effectively treat their patients faster than ever before, improving patient care and reducing costs. The T2Dx Instrument, T2Candida Panel, T2Bacteria Panel, T2Resistance Panel, and T2SARS-CoV-2 Panel available from TTOO are all powered by the T2MR (T2 Magnetic Resonance) technology. TTOO is developing future products such as the T2Cauris Panel, the T2Lyme Panel, and additional products to detect infectious pathogens that share antimicrobial resistance genes and biothreat pathogens.

Eleven new employees received inducement awards from T2 Biosystems yesterday.
- TTOO made the awards under its Inducement Award Plan on July 8, 2021.
- On March 1, 2018, the program was adopted by TTOO, amended and restated on January 8, 2020.
- Through TTOO’s Equity Incentive Program, new employees of the company are awarded equity awards.
- As part of the inducement awards, employees received options to buy 321,000 shares of TTOO common stock, which were granted for a ten-year period.
- On July 8, 2021, TTOO Biosystems common stock closed at $1.06 per share on the Nasdaq Capital Market, which was the exercise price of the options.
- Over the next four years, employees’ options vest 25% on the first anniversary of their hire date, and the remainder vesting after that in equal monthly installments.
How was the award granted?

An independent compensation committee of the board of directors of TTOO approved the award. According to Nasdaq Marketplace Rules, the award was granted as an inducement material to entice the new employee to become employed by T2 Biosystems (TTOO).
July 20, 2021
NVIDIA Corp. (NVDA) Stock Plummets Following Implementation of Stock Split

NVIDIA Corp. (NVDA) stock prices were up 3.41% as of the market close on July 19^th, 2021, bringing the price per share up to USD$751.19 at the end of the trading day. Subsequent premarket fluctuations have seen the stock plummet by 74.79%, bringing it down to USD$189.40.

NVDA Stock Split

The company’s stock has been climbing steadily and substantially for quite some time now, coming in at more than USD$800 per share as of the end of June 2021. May 2021 saw NVDA announce a stock split that would see each share of common stock being divided into 4 whole shares of common stock. As of the market opening on July 20^th, 2021, NVDA shares will trade on a split-adjusted basis. Accordingly, the price of each share will be reduced drastically, which is to be expected given the influx of a number of shares outstanding.

Effect of Stock Split

While stock splits obviously affect the price of each share, they do not have a tangible effect on the actual value of the company or the value of its shares. With changes being limited to the number of shares and according to the price of each, fundamentals remain unchanged, as does the long-term outlook of the company. Following the four to one stock split, shareholders of record will find themselves to own four times as many shares as before the split, with the actual value of their investment staying the same.

Healthy Financials

The company’s revenue report for the first quarter of 2021 reported USD$5.66 billion, a massive 84% year-over-year increase from the numbers reported in the prior-year quarter. This was largely motivated by a doubling of the company’s gaming revenue, which was up to USD$2.76 billion, as well as a 79% year-over-year improvement in data center revenue. Earnings per share were also up, by 106% over the course of the year to hit USD$3.66.

Investor Accessibility

The resulting reduction in price per share following a stock split has the potential to positively impact longer-term gains because of the increased accessibility. This effect, however, is mitigated partially by the introduction of partial shares, which allow investors to buy fractions of shares. This offers investors the accessibility that is not time-bound as opposed to investors having to wait and time their investments around the implementation of stock splits.

Future Outlook for NVDA

Armed with its sustained trajectory of success over the past few quarters, NVDA is poised to capitalize on its momentum as it allocates resources to maintain its steam. Investors are hopeful that management will be able to turn the stock split around to usher in additional growth from the added exposure and accessibility.

July 20, 2021
Orbital Energy Group Inc. (OEG) stock surged in the premarket trading session; find out why

In the premarket trading session, shares were surging by 4.17% to trade at $4.25 for the (OEG stock), at last check. OEG stock previously closed the session at a gain of 3.29% at $4.08. In the past year up to date, the OEG stock volume traded 2.29 million shares today, this compares to lower when looked at the average daily volume of 8.46 million shares within the past 50 days. In the past year and past week, OEG shares have risen by 553.64% and shed by -4.90% respectively. In the past three and six months, the OEG stock has gained 7.37%, and added 2.00% respectively.

First, let us talk about Orbital Energy Group

Orbital Energy Group is a utilities-based diversified company that specifically focuses on the provision of electric power. It also provides on the medium of generating electric power for example it sells solar and integrated energy infrastructure and services. The OEG stock has established its base of operations primarily for the market of United States, United Kingdoms and then internationally. The services related to electric power and infrastructure development include engineering, construction services, procurement related to renewable energy generation products. These services provide a backend to the renewable energy generation products of the company, mainly focused on utility-scale solar construction. The designs, redesigns, fixes, and maintenance with electric force transmission and dispersion framework and substation offices are all part of company’s services. It likewise offers types of assistance to the electric transmission and substation, modern, correspondence pinnacles, and fiasco reclamation market areas. Also, the organization offers petroleum gas framework and cutting edge innovation, including meteringand far off telemetry units; and customized gas designing answers for the gas utilities, power age, outflows, fabricating, and car enterprises under the GasPT and VE Technology names. The organization was established in 1998 and is settled in Houston, Texas.

Greater commercial access as contracts come OEG stock’s way

The company has announced that it has been granted a task by a significant U.S. cell transporter to introduce a circulated radio wires framework known as distributed antennae suste (DAS) in a huge Atlantic Athletic Conference (ACC) college arena. This venture perceives GTS’s capacity to convey top notch designing and development administrations. It makes an incentive for OEG stock by giving DAS as from a main media communications administrations supplier for a significant college stadium. It likewise reflects how DAS projects are presently returning on the web, in the wake of being generally deferred because of the pandemic.

The company had initiated joing of the Russell Microcap® Index at the finish of the 2021 Russell files yearly reconstitution, compelling after the U.S. market opens on, as per a starter rundown of augmentations distributed by the FTSE Russell on June 4, 2021.

The enrollment stays set up for one year, which implies programmed incorporation in the suitable development and worth style lists. Orbital Energy Group’s expansion to this profoundly regarded list is another achievement for the Company by upgrading attention to OEG to a bigger number of establishments and financial backers, profiting Oshareholders with further developed liquidity.

July 20, 2021
Does This Explain The Rise In EXTR Stock?
In Monday’s after-hour session, Extreme Networks Inc. (EXTR) shares rose 10.15 percent to $10.53. During the regular trading session, Extreme Networks stock lost -9.21%, closing at $9.56. The average daily trading volume for EXTR in the last 50 days is 1.05 million shares, which is below the 1.88 million-share trading volume recorded today.

In the last five days, EXTR shares have advanced -12.85%; however, over the past month, the stock has lost -13.80%. EXTR has gained 113.87 percent so far this year, with its price up 0.63% over the past three months. As the EXTR stock has recovered in extended trades after losing ground in regular trades due to a lack of current news, we can discuss recent developments to obtain a more comprehensive understanding of EXTR.

Has EXTR been going well lately?

As a provider of effortless networking experiences, Extreme Networks empowers us all to prosper. EXTR utilizes the power of machine learning, artificial intelligence, analytics, and automation to push the boundaries of technology. The EXTR top-rated services and support are used by over 50,000 customers around the world to accelerate their digital transformation efforts and deliver unprecedented progress.

It has recently been announced that Extreme Networks plans to release financial results for the fifth quarter, ended June 30, 2021, and the full year.
- In conjunction with the earnings announcement, EXTR will hold a webcast and conference call on Wednesday, July 28, 2021.
- On Wednesday, July 28 at 8:00 a.m. ET, EXTR will host a conference call and webcast.
- Webcast will be accessible via the Investors section of the EXTR website.
- The webcast will be streamed live over the internet, so EXTR investors can access it through the website.
- Participants can join EXTR’s conference call by dialing 1 (877) 303-9826 toll free or 1 (224) 357-2194 from abroad.
- Replays of conference calls will be available for 7 days after the event.
- According to the 650 Group’s June 2021 Cloud-Managed Network Services Report, Extreme Networks is the second-ranked brand in the cloud-managed network services industry and one of the fastest growing cloud-managed network service providers.
- EXTR outpaces the market, including the leader, and possesses more market share than the third and fourth ranked vendors combined.
How EXTR is performing in the cloud market?

An expanding number of enterprises have adopted cloud services over the past year, driving rapid growth for EXTR in the market of cloud-managed networks services. Extreme Networks (EXTR) is punching above its weight in the rapidly growing cloud and wireless technology market, and the company anticipates that the market will continue to expand as vendors like Extreme Networks expand their cloud offerings.
July 20, 2021